1
|
Li M, Geng C, Han Y, Guan F, Liu Y, Shu D, Tang X. Incorporating boron distribution variations in microdosimetric kinetic model-based relative biological effectiveness calculations for boron neutron capture therapy. RADIATION PROTECTION DOSIMETRY 2024; 200:1319-1328. [PMID: 39010755 DOI: 10.1093/rpd/ncae158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/27/2023] [Revised: 06/14/2024] [Accepted: 06/26/2024] [Indexed: 07/17/2024]
Abstract
This study introduces the MKM_B model, an approach derived from the MKM model, designed to evaluate the biological effectiveness of Boron Neutron Capture Therapy (BNCT) in the face of challenges from varying microscopic boron distributions. The model introduces a boron compensation factor, allowing for the assessment of compound Biological Effectiveness (CBE) values for different boron distributions. Utilizing the TOPAS simulation platform, the lineal energy spectrum of particles in BNCT was simulated, and the sensitivity of the MKM_B model to parameter variations and the influence of cell size on the model were thoroughly investigated. The CBE values for 10B-boronphenylalanine (BPA) and 10B-sodium (BSH) were determined to be 3.70 and 1.75, respectively. These calculations were based on using the nucleus radius of 2.5 μm and the cell radius of 5 μm while considering a 50% surviving fraction. It was observed that as cell size decreased, the CBE values for both BPA and BSH increased. Additionally, the model parameter rd was identified as having the most significant impact on CBE, with other parameters showing moderate effects. The development of the MKM_B model enables the accurate prediction of CBE under different boron distributions in BNCT. This model offers a promising approach to optimize treatment planning by providing increased accuracy in biological effectiveness.
Collapse
Affiliation(s)
- Mingzhu Li
- Department of Nuclear Science and Technology, Nanjing University of Aeronautics and Astronautics, Nanjing, 211106, China
- Joint International Research Laboratory on Advanced Particle Therapy, Nanjing University of Aeronautics and Astronautics, Nanjing, 211100, China
| | - Changran Geng
- Department of Nuclear Science and Technology, Nanjing University of Aeronautics and Astronautics, Nanjing, 211106, China
- Joint International Research Laboratory on Advanced Particle Therapy, Nanjing University of Aeronautics and Astronautics, Nanjing, 211100, China
| | - Yang Han
- Department of Nuclear Science and Technology, Nanjing University of Aeronautics and Astronautics, Nanjing, 211106, China
- Joint International Research Laboratory on Advanced Particle Therapy, Nanjing University of Aeronautics and Astronautics, Nanjing, 211100, China
| | - Fada Guan
- Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, Connecticut, 06530, United States
| | - Yuanhao Liu
- Department of Nuclear Science and Technology, Nanjing University of Aeronautics and Astronautics, Nanjing, 211106, China
- Joint International Research Laboratory on Advanced Particle Therapy, Nanjing University of Aeronautics and Astronautics, Nanjing, 211100, China
- Neuboron Medtech Ltd., Nanjing, Jiangsu, 211112, China
| | - Diyun Shu
- Department of Nuclear Science and Technology, Nanjing University of Aeronautics and Astronautics, Nanjing, 211106, China
- Joint International Research Laboratory on Advanced Particle Therapy, Nanjing University of Aeronautics and Astronautics, Nanjing, 211100, China
- Neuboron Medtech Ltd., Nanjing, Jiangsu, 211112, China
| | - Xiaobin Tang
- Department of Nuclear Science and Technology, Nanjing University of Aeronautics and Astronautics, Nanjing, 211106, China
- Joint International Research Laboratory on Advanced Particle Therapy, Nanjing University of Aeronautics and Astronautics, Nanjing, 211100, China
| |
Collapse
|
2
|
Fujikawa Y, Kawabata S, Tsujino K, Yamada H, Kashiwagi H, Yagi R, Hiramatsu R, Nonoguchi N, Takami T, Sasaki A, Hu N, Takata T, Tanaka H, Suzuki M, Wanibuchi M. Boron neutron capture therapy delays the decline in neurological function in a mouse model of metastatic spinal tumors. Cancer Sci 2024; 115:2774-2785. [PMID: 38860412 PMCID: PMC11309935 DOI: 10.1111/cas.16245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2024] [Revised: 05/16/2024] [Accepted: 05/31/2024] [Indexed: 06/12/2024] Open
Abstract
Metastatic spinal tumors are increasingly prevalent due to advancements in cancer treatment, leading to prolonged survival rates. This rising prevalence highlights the need for developing more effective therapeutic approaches to address this malignancy. Boron neutron capture therapy (BNCT) offers a promising solution by delivering targeted doses to tumors while minimizing damage to normal tissue. In this study, we evaluated the efficacy and safety of BNCT as a potential therapeutic option for spine metastases in mouse models induced by A549 human lung adenocarcinoma cells. The animal models were randomly allocated into three groups: untreated (n = 10), neutron irradiation only (n = 9), and BNCT (n = 10). Each mouse was administered 4-borono-L-phenylalanine (250 mg/kg) intravenously, followed by measurement of boron concentrations 2.5 h later. Overall survival, neurological function of the hindlimb, and any adverse events were assessed post irradiation. The tumor-to-normal spinal cord and blood boron concentration ratios were 3.6 and 2.9, respectively, with no significant difference observed between the normal and compressed spinal cord tissues. The BNCT group exhibited significantly prolonged survival rates compared with the other groups (vs. untreated, p = 0.0015; vs. neutron-only, p = 0.0104, log-rank test). Furthermore, the BNCT group demonstrated preserved neurological function relative to the other groups (vs. untreated, p = 0.0004; vs. neutron-only, p = 0.0051, multivariate analysis of variance). No adverse events were observed post irradiation. These findings indicate that BNCT holds promise as a novel treatment modality for metastatic spinal tumors.
Collapse
Affiliation(s)
- Yoshiki Fujikawa
- Department of NeurosurgeryOsaka Medical and Pharmaceutical UniversityOsakaJapan
| | - Shinji Kawabata
- Department of NeurosurgeryOsaka Medical and Pharmaceutical UniversityOsakaJapan
| | - Kohei Tsujino
- Department of NeurosurgeryOsaka Medical and Pharmaceutical UniversityOsakaJapan
| | - Hironori Yamada
- Department of NeurosurgeryOsaka Medical and Pharmaceutical UniversityOsakaJapan
| | - Hideki Kashiwagi
- Department of NeurosurgeryOsaka Medical and Pharmaceutical UniversityOsakaJapan
| | - Ryokichi Yagi
- Department of NeurosurgeryOsaka Medical and Pharmaceutical UniversityOsakaJapan
| | - Ryo Hiramatsu
- Department of NeurosurgeryOsaka Medical and Pharmaceutical UniversityOsakaJapan
| | - Naosuke Nonoguchi
- Department of NeurosurgeryOsaka Medical and Pharmaceutical UniversityOsakaJapan
| | - Toshihiro Takami
- Department of NeurosurgeryOsaka Medical and Pharmaceutical UniversityOsakaJapan
| | - Akinori Sasaki
- Kansai BNCT Medical CenterOsaka Medical and Pharmaceutical UniversityOsakaJapan
| | - Naonori Hu
- Kansai BNCT Medical CenterOsaka Medical and Pharmaceutical UniversityOsakaJapan
| | - Takushi Takata
- Institute for Integrated Radiation and Nuclear ScienceKyoto UniversityOsakaJapan
| | - Hiroki Tanaka
- Institute for Integrated Radiation and Nuclear ScienceKyoto UniversityOsakaJapan
| | - Minoru Suzuki
- Institute for Integrated Radiation and Nuclear ScienceKyoto UniversityOsakaJapan
| | - Masahiko Wanibuchi
- Department of NeurosurgeryOsaka Medical and Pharmaceutical UniversityOsakaJapan
| |
Collapse
|
3
|
Kielly M, Caracciolo A, Chacon A, Vohradsky J, Di Vita D, Hamato A, Tashima H, Franklin DR, Yamaya T, Rosenfeld A, Carminati M, Fiorini C, Guatelli S, Safavi-Naeini M. First experimental demonstration of real-time neutron capture discrimination in helium and carbon ion therapy. Sci Rep 2024; 14:2601. [PMID: 38297114 PMCID: PMC10831067 DOI: 10.1038/s41598-024-52162-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2023] [Accepted: 01/15/2024] [Indexed: 02/02/2024] Open
Abstract
This work provides the first experimental proof of an increased neutron capture photon signal following the introduction of boron to a PMMA phantom during helium and carbon ion therapies in Neutron Capture Enhanced Particle Therapy (NCEPT). NCEPT leverages [Formula: see text]B neutron capture, leading to the emission of detectable 478 keV photons. Experiments were performed at the Heavy Ion Medical Accelerator in Chiba, Japan, with two Poly(methyl methacrylate) (PMMA) targets, one bearing a boron insert. The BeNEdiCTE gamma-ray detector measured an increase in the 478 keV signal of 45 ± 7% and 26 ± 2% for carbon and helium ion irradiation, respectively. Our Geant4 Monte Carlo simulation model, developed to investigate photon origins, found less than 30% of detected photons originated from the insert, while boron in the detector's circuit boards contributed over 65%. Further, the model investigated detector sensitivity, establishing its capability to record a 10% increase in 478 keV photon detection at a target [Formula: see text]B concentration of 500 ppm using spectral windowing alone, and 25% when combined with temporal windowing. The linear response extended to concentrations up to 20,000 ppm. The increase in the signal in all evaluated cases confirm the potential of the proposed detector design for neutron capture quantification in NCEPT.
Collapse
Affiliation(s)
- Marissa Kielly
- Australian Nuclear Science and Technology Organisation (ANSTO), Lucas Heights, Australia
- Centre for Medical Radiation Physics, University of Wollongong, Wollongong, Australia
| | - Anita Caracciolo
- Dipartimento di Elettronica, Informazione e Bioingegneria, Politecnico di Milano, Milan, Italy
- Istituto Nazionale di Fisica Nucleare (INFN), Sezione di Milano, Milan, Italy
| | - Andrew Chacon
- Australian Nuclear Science and Technology Organisation (ANSTO), Lucas Heights, Australia
| | - James Vohradsky
- Centre for Medical Radiation Physics, University of Wollongong, Wollongong, Australia
| | - Davide Di Vita
- Dipartimento di Elettronica, Informazione e Bioingegneria, Politecnico di Milano, Milan, Italy
- Istituto Nazionale di Fisica Nucleare (INFN), Sezione di Milano, Milan, Italy
| | - Akram Hamato
- Imaging Physics Group, Department of Advanced Nuclear Medicine Sciences, National Institutes for Quantum Science and Technology (QST), Inage-ku, Chiba, Japan
| | - Hideaki Tashima
- Imaging Physics Group, Department of Advanced Nuclear Medicine Sciences, National Institutes for Quantum Science and Technology (QST), Inage-ku, Chiba, Japan
| | - Daniel R Franklin
- School of Electrical and Data Engineering, University of Technology Sydney, Sydney, Australia
| | - Taiga Yamaya
- Imaging Physics Group, Department of Advanced Nuclear Medicine Sciences, National Institutes for Quantum Science and Technology (QST), Inage-ku, Chiba, Japan
| | - Anatoly Rosenfeld
- Centre for Medical Radiation Physics, University of Wollongong, Wollongong, Australia
| | - Marco Carminati
- Dipartimento di Elettronica, Informazione e Bioingegneria, Politecnico di Milano, Milan, Italy
- Istituto Nazionale di Fisica Nucleare (INFN), Sezione di Milano, Milan, Italy
| | - Carlo Fiorini
- Dipartimento di Elettronica, Informazione e Bioingegneria, Politecnico di Milano, Milan, Italy
- Istituto Nazionale di Fisica Nucleare (INFN), Sezione di Milano, Milan, Italy
| | - Susanna Guatelli
- Centre for Medical Radiation Physics, University of Wollongong, Wollongong, Australia
| | - Mitra Safavi-Naeini
- Australian Nuclear Science and Technology Organisation (ANSTO), Lucas Heights, Australia.
| |
Collapse
|
4
|
Khalil A, Adam MSS. Nucleoside Scaffolds and Carborane Clusters for Boron Neutron Capture Therapy: Developments and Future Perspective. Curr Med Chem 2024; 31:5739-5754. [PMID: 37818562 DOI: 10.2174/0109298673245020230929152030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2023] [Revised: 06/19/2023] [Accepted: 08/24/2023] [Indexed: 10/12/2023]
Abstract
Nucleosides containing carboranes are one of the most important boron delivery agents for boron neutron capture therapy, BNCT, which are good substrates of hTK1. The development of several nucleosides containing carboranes at early stages led to the discovery of the first generation of 3CTAs by incorporating a hydrocarbon spacer between the thymidine scaffold and carborane cluster and attaching dihydroxylpropyl group on the second carbon (C2) atom of the carborane cluster (e.g., N5 and N5-2OH). Phosphorylation rate, tumor cellular uptake, and retention have been evaluated in parallel to change the length of the tether arm of spacers in these compounds. Many attempts were reported and discussed to overcome the disadvantage of the first generation of 3CTAs by a) incorporating modified spacers between thymidine and carborane clusters, such as ethyleneoxide, polyhydroxyl, triazole, and tetrazole units, b) attaching hydrophilic groups at C2 of the carborane cluster, c) transforming lipophilic closo-carboranes to hydrophilic nidocarborane. The previous modifications represented the second generation of 3CTAs to improve the hydrogen bond formation with the hTK1 active site. Moreover, amino acid prodrugs were developed to enhance biological and physicochemical properties. The structure-activity relationship (SAR) of carboranyl thymidine analogues led to the roadmap for the development of the 3rd generation of the 3CTAs for BNCT.
Collapse
Affiliation(s)
- Ahmed Khalil
- Department of Chemistry, College of Science, King Faisal University, Al Ahsa 31982, Saudi Arabia
- Department of Chemistry, Faculty of Science, Zagazig University, Zagazig 44519, Egypt
| | - Mohamed Shaker S Adam
- Department of Chemistry, College of Science, King Faisal University, Al Ahsa 31982, Saudi Arabia
- Department of Chemistry, Faculty of Science, Sohag University, Sohag 82534, Egypt
| |
Collapse
|
5
|
Hattori Y, Andoh T, Kawabata S, Hu N, Michiue H, Nakamura H, Nomoto T, Suzuki M, Takata T, Tanaka H, Watanabe T, Ono K. Proposal of recommended experimental protocols for in vitro and in vivo evaluation methods of boron agents for neutron capture therapy. JOURNAL OF RADIATION RESEARCH 2023; 64:859-869. [PMID: 37717596 PMCID: PMC10665309 DOI: 10.1093/jrr/rrad064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/16/2023] [Revised: 06/19/2023] [Accepted: 08/19/2023] [Indexed: 09/19/2023]
Abstract
Recently, boron neutron capture therapy (BNCT) has been attracting attention as a minimally invasive cancer treatment. In 2020, the accelerator-based BNCT with L-BPA (Borofalan) as its D-sorbitol complex (Steboronine®) for head and neck cancers was approved by Pharmaceutical and Medical Devices Agency for the first time in the world. As accelerator-based neutron generation techniques are being developed in various countries, the development of novel tumor-selective boron agents is becoming increasingly important and desired. The Japanese Society of Neutron Capture Therapy believes it is necessary to propose standard evaluation protocols at each stage in the development of boron agents for BNCT. This review summarizes recommended experimental protocols for in vitro and in vivo evaluation methods of boron agents for BNCT based on our experience with L-BPA approval.
Collapse
Affiliation(s)
- Yoshihide Hattori
- Research Center for BNCT, Osaka Metropolitan University, 1-1 Gakuen-cho, Nakaku, Sakai 599-8531, Japan
| | - Tooru Andoh
- Laboratory of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Kobe 650-8586, Japan
| | - Shinji Kawabata
- Department of Neurosurgery, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki-shi, Osaka 569-8686, Japan
| | - Naonori Hu
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki-shi, Osaka 569-8686, Japan
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2, Asashiro-Nishi, Kumatori-cho, Sennan-gun 590-0494 Japan
| | - Hiroyuki Michiue
- Neutron Therapy Research Center, Okayama University, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan
| | - Hiroyuki Nakamura
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 4259 Nagatsuta-cho, Midori-ku, Yokohama 226-8503, Japan
| | - Takahiro Nomoto
- Department of Life Sciences, Graduate School of Arts and Sciences, The University of Tokyo, 3-8-1 Komaba, Meguro-ku, Tokyo 153-8902, Japan
| | - Minoru Suzuki
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2, Asashiro-Nishi, Kumatori-cho, Sennan-gun 590-0494 Japan
| | - Takushi Takata
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2, Asashiro-Nishi, Kumatori-cho, Sennan-gun 590-0494 Japan
| | - Hiroki Tanaka
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2, Asashiro-Nishi, Kumatori-cho, Sennan-gun 590-0494 Japan
| | - Tsubasa Watanabe
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2, Asashiro-Nishi, Kumatori-cho, Sennan-gun 590-0494 Japan
| | - Koji Ono
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki-shi, Osaka 569-8686, Japan
| |
Collapse
|
6
|
Chang CH, Chen CJ, Yu CF, Tsai HY, Chen FH, Chiang CS. Targeting M-MDSCs enhances the therapeutic effect of BNCT in the 4-NQO-induced murine head and neck squamous cell carcinoma model. Front Oncol 2023; 13:1263873. [PMID: 37886177 PMCID: PMC10598372 DOI: 10.3389/fonc.2023.1263873] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2023] [Accepted: 09/15/2023] [Indexed: 10/28/2023] Open
Abstract
Purpose Malignant head and neck squamous cell carcinoma (HNSCC) is characterized by a poor prognosis and resistance to conventional radiotherapy. Infiltrating myeloid-derived suppressive cells (MDSCs) is prominent in HNSCC and is linked to immune suppression and tumor aggressiveness. This study aimed to investigate the impact of boron neutron capture therapy (BNCT) on the MDSCs in the tumor microenvironment and peripheral blood and to explore the potential for MDSCs depletion combined with BNCT to reactivate antitumor immunity. Methods and materials Carcinogen, 4-NQO, -induced oral tumors were irradiated with a total physical dose of 2 Gy BNCT in Tsing Hua Open Reactor (THOR). Flow cytometry and immunohistochemistry accessed the dynamics of peripheral MDSCs and infiltrated MDSCs within the tumor microenvironment. Mice were injected with an inhibitor of CSF-1 receptor (CSF-1R), PLX3397, to determine whether modulating M-MDSCs could affect mice survival after BNCT. Results Peripheral CD11b+Ly6ChighLy6G- monocytic-MDSCs (M-MDSCs), but not CD11b+Ly6CloLy6Ghigh polymorphonuclear-MDSCs (PMN-MDSCs), increased as tumor progression. After BNCT treatment, there were temporarily decreased and persistent increases of M-MDSCs thereafter, either in peripheral blood or in tumors. The administration of PLX-3397 hindered BNCT-caused M-MDSCs infiltration, prolonged mice survival, and activated tumor immunity by decreasing tumor-associated macrophages (TAMs) and increasing CD8+ T cells. Conclusion M-MDSCs were recruited into 4-NQO-induced tumors after BNCT, and their number was also increased in peripheral blood. Assessment of M-MDSCs levels in peripheral blood could be an index to determine the optimal intervention window. Their temporal alteration suggests an association with tumor recurrence after BNCT, making M-MDSCs a potential intervention target. Our preliminary results showed that PLX-3397 had strong M-MDSCs, TAMs, and TIL (tumor-infiltrating lymphocyte) modulating effects that could synergize tumor control when combined with BNCT.
Collapse
Affiliation(s)
- Chun-Hsiang Chang
- Department of Biomedical Engineering and Environment Sciences, National Tsing Hua University, Hsinchu, Taiwan
| | - Chi-Jui Chen
- Department of Biomedical Engineering and Environment Sciences, National Tsing Hua University, Hsinchu, Taiwan
| | - Ching-Fang Yu
- Institute for Radiological Research, Chang Gung University, Taoyuan, Taiwan
- Department of Radiation Oncology, Chang Gung Memorial Hospital Linkou Branch, Taoyuan, Taiwan
| | - Hui-Yu Tsai
- Institute of Nuclear Engineering and Science, National Tsing Hua University, Hsinchu, Taiwan
| | - Fang-Hsin Chen
- Institute of Nuclear Engineering and Science, National Tsing Hua University, Hsinchu, Taiwan
| | - Chi-Shiun Chiang
- Department of Biomedical Engineering and Environment Sciences, National Tsing Hua University, Hsinchu, Taiwan
- Institute of Nuclear Engineering and Science, National Tsing Hua University, Hsinchu, Taiwan
| |
Collapse
|
7
|
Tamari Y, Takata T, Takeno S, Tanaka H, Yamazaki H, Yamada K, Suzuki M. Influence of Boron Neutron Capture Therapy on Normal Liver Tissue. Radiat Res 2022; 198:368-374. [PMID: 35904430 DOI: 10.1667/rade-22-00018.1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2022] [Accepted: 06/17/2022] [Indexed: 11/03/2022]
Abstract
Radiation-induced liver diseases, including liver fibrosis, occurs when radiation damages the liver. Basic research on hepatic fibrosis, which is a late radiation injury, is necessary for evaluating adverse liver events occurring after boron neutron capture therapy. This study was conducted to establish a method for analyzing the negative effect such as fibrosis in the liver tissue after boron neutron capture therapy. Female C57BL6 mice were injected with p-boronophenylalanine solution subcutaneously at 2 h before neutron irradiation. Masson trichrome staining was performed to determine the degree of liver fibrosis. The degree of fat accumulation in mouse normal liver tissue after boron neutron capture therapy was evaluated using hematoxylin and eosin staining and triglyceride quantification. Western blotting was performed to determine the expression level of Sonic Hedgehog. Liver fat accumulation and fibrosis were significantly increased in the neutron irradiation group injected with p-boronophenylalanine compared with control group. In addition, Sonic Hedgehog expression was increased in response to boron neutron capture therapy-induced liver injury and was involved in liver fibrosis. Hepatocellular fat accumulation and Hedgehog signaling activation may be indicators of adverse events related to boron neutron capture therapy associated with liver fibrosis.
Collapse
Affiliation(s)
- Yuki Tamari
- Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, Japan.,Radiation Oncology Research Laboratory, Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2-1010, Asashiro-nishi, Kumatori-cho, Sennan-gun, Osaka, Japan
| | - Takushi Takata
- Radiation Oncology Research Laboratory, Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2-1010, Asashiro-nishi, Kumatori-cho, Sennan-gun, Osaka, Japan
| | - Satoshi Takeno
- Radiation Oncology Research Laboratory, Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2-1010, Asashiro-nishi, Kumatori-cho, Sennan-gun, Osaka, Japan
| | - Hiroki Tanaka
- Radiation Oncology Research Laboratory, Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2-1010, Asashiro-nishi, Kumatori-cho, Sennan-gun, Osaka, Japan
| | - Hideya Yamazaki
- Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, Japan
| | - Kei Yamada
- Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, Japan
| | - Minoru Suzuki
- Radiation Oncology Research Laboratory, Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2-1010, Asashiro-nishi, Kumatori-cho, Sennan-gun, Osaka, Japan
| |
Collapse
|
8
|
Response of Normal Tissues to Boron Neutron Capture Therapy (BNCT) with 10B-Borocaptate Sodium (BSH) and 10B-Paraboronophenylalanine (BPA). Cells 2021; 10:cells10112883. [PMID: 34831105 PMCID: PMC8616460 DOI: 10.3390/cells10112883] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2021] [Revised: 10/22/2021] [Accepted: 10/22/2021] [Indexed: 02/07/2023] Open
Abstract
Boron neutron capture therapy (BNCT) is a cancer-selective radiotherapy that utilizes the cancer targeting 10B-compound. Cancer cells that take up the compound are substantially damaged by the high liner energy transfer (LET) particles emitted mainly from the 10B(n, α7Li reaction. BNCT can minimize the dose to normal tissues, but it must be performed within the tolerable range of normal tissues. Therefore, it is important to evaluate the response of normal tissues to BNCT. Since BNCT yields a mixture of high and low LET radiations that make it difficult to understand the radiobiological basis of BNCT, it is important to evaluate the relative biological effectiveness (RBE) and compound biological effectiveness (CBE) factors for assessing the responses of normal tissues to BNCT. BSH and BPA are the only 10B-compounds that can be used for clinical BNCT. Their biological behavior and cancer targeting mechanisms are different; therefore, they affect the CBE values differently. In this review, we present the RBE and CBE values of BPA or BSH for normal tissue damage by BNCT irradiation. The skin, brain (spinal cord), mucosa, lung, and liver are included as normal tissues. The CBE values of BPA and BSH for tumor control are also discussed.
Collapse
|
9
|
Fukuda H. Boron Neutron Capture Therapy (BNCT) for Cutaneous Malignant Melanoma Using 10B-p-Boronophenylalanine (BPA) with Special Reference to the Radiobiological Basis and Clinical Results. Cells 2021; 10:2881. [PMID: 34831103 PMCID: PMC8616259 DOI: 10.3390/cells10112881] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2021] [Revised: 10/22/2021] [Accepted: 10/22/2021] [Indexed: 01/22/2023] Open
Abstract
BNCT is a radiotherapeutic method for cancer treatment that uses tumor-targeting 10B-compounds. BNCT for cutaneous melanoma using BPA, a phenylalanine derivative, was first initiated by Mishima et al. in 1987. This article reviews the radiobiological basis of melanoma control and damage to normal tissues as well as the results of clinical studies. Experimental studies showed that the compound biological effectiveness (CBE) values of the 10B (n, α)7Li reaction for melanoma control ranged from 2.5 to 3.3. The CBE values of the 10B (n, α)7Li reaction for skin damage ranged from 2.4 to 3.7 with moist desquamation as the endpoint. The required single radiation dose for controlling human melanoma was estimated to be 25 Gy-Eq or more by analyzing the 50% tumor control dose data of conventional fractionated radiotherapy. From the literature, the maximum permissible dose to human skin by single irradiation was estimated to be 18 Gy-Eq. With respect to the pharmacokinetics of BPA in patients with melanoma treated with 85-350 mg/kg BPA, the melanoma-to-blood ratio ranged from 2.1-3.8 and the skin-to-blood ratio was 1.31 ± 0.22. Good local tumor control and long-term survival of the patients were achieved in two clinical trials of BNCT conducted in Japan.
Collapse
Affiliation(s)
- Hiroshi Fukuda
- Department of Radiology, Tohoku Medical and Pharmaceutical University, Sendai 983-8536, Japan
| |
Collapse
|
10
|
A Novel Approach to Design and Evaluate BNCT Neutron Beams Combining Physical, Radiobiological, and Dosimetric Figures of Merit. BIOLOGY 2021; 10:biology10030174. [PMID: 33652642 PMCID: PMC7996903 DOI: 10.3390/biology10030174] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/18/2021] [Revised: 02/13/2021] [Accepted: 02/19/2021] [Indexed: 11/17/2022]
Abstract
(1) Background:The quality of neutron beams for Boron Neutron Capture Therapy (BNCT) is currently defined by its physical characteristics in air. Recommendations exist to define whether a designed beam is useful for clinical treatment. This work presents a new way to evaluate neutron beams based on their clinical performance and on their safety, employing radiobiological quantities. (2) Methods: The case study is a neutron beam for deep-seated tumors from a 5 MeV proton beam coupled to a beryllium target. Physical Figures of Merit were used to design five beams; however, they did not allow a clear ranking of their quality in terms of therapeutic potential. The latter was then evaluated based on in-phantom dose distributions and on the calculation of the Uncomplicated Tumor Control Probability (UTCP). The safety of the beams was also evaluated calculating the in-patient out-of-beam dosimetry. (3) Results: All the beams ensured a UTCP comparable to the one of a clinical beam in phantom; the safety criterion allowed to choose the best candidate. When this was tested in the treatment planning of a real patient treated in Finland, the UTCP was still comparable to the one of the clinical beam. (4) Conclusions: Even when standard physical recommendations are not met, radiobiological and dosimetric criteria demonstrate to be a valid tool to select an effective and safe beam for patient treatment.
Collapse
|
11
|
Wróblewska A, Szermer-Olearnik B, Pajtasz-Piasecka E. Nanocząstki o wysokiej zawartości boru
jako potencjalne nośniki w terapii
borowo-neutronowej. POSTEP HIG MED DOSW 2021. [DOI: 10.5604/01.3001.0014.7760] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Podstawą terapii borowo-neutronowej (boron neutron capture therapy, BNCT) jest selektywne
dostarczenie boru do komórek nowotworowych, a następnie napromienienie zmienionego
chorobowo miejsca wiązką neutronów. W wyniku tego procesu dochodzi do rozszczepienia
jądra izotopu 10B, co powoduje uwolnienie energii niszczącej komórki nowotworowe.
Mimo że badania związane z BNCT trwają od lat 50. XX wieku, pozostaje ona wciąż terapią
eksperymentalną. Jest to związane m.in. z brakiem nośników umożliwiających szybkie i skuteczne
wprowadzanie 10B do środowiska nowotworu. Tak więc często podnoszonym zagadnieniem
i jednym z głównych wyzwań dla rozwoju BNCT, jest poszukiwanie selektywnych
związków dostarczających wymaganą ilość tego pierwiastka. Istotnym aspektem są badania
nad nanometrycznymi strukturami, takimi jak liposomy zawierające związki bogate w bor
lub nieorganiczne nanocząstki – węglik boru czy azotek boru. Ze względu na dużą zawartość
boru oraz możliwość modyfikacji powierzchni tych nanocząstek, mogą się one okazać
wyjątkowo atrakcyjnym narzędziem w celowanej BNCT. Równie ważnym problemem tej terapii
jest opracowanie precyzyjnych powiązań między źródłem neutronów, specyfiką wiązki
a rodzajem zastosowanego nośnika. W artykule wskazujemy na wysoki potencjał związków
bogatych w bor jako nośników w celowanej terapii borowo-neutronowej.
Collapse
Affiliation(s)
- Anna Wróblewska
- Instytut Immunologii i Terapii Doświadczalnej im. Ludwika Hirszfelda Polskiej Akademii Nauk we Wrocławiu
| | - Bożena Szermer-Olearnik
- Instytut Immunologii i Terapii Doświadczalnej im. Ludwika Hirszfelda Polskiej Akademii Nauk we Wrocławiu
| | - Elżbieta Pajtasz-Piasecka
- Instytut Immunologii i Terapii Doświadczalnej im. Ludwika Hirszfelda Polskiej Akademii Nauk we Wrocławiu
| |
Collapse
|
12
|
Nakai K, Endo K, Yoshida F, Koka M, Yamada N, Satoh T, Tsurubuchi T, Matsumura A, Matsumoto Y, Sakurai H. Boron analysis and imaging of cells with 2-hr BPA exposure by using micro-proton particle-induced gamma-ray emission (PIGE). Appl Radiat Isot 2020; 165:109334. [PMID: 32739796 DOI: 10.1016/j.apradiso.2020.109334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2019] [Revised: 07/05/2020] [Accepted: 07/08/2020] [Indexed: 10/23/2022]
Abstract
Particle-induced gamma-ray emission (PIGE), which measures prompt gamma rays at 428 keV from 10B (p, p'γ) 7Be, was used to confirm the boron distribution within 2hr-BPA-exposed cells. Distribution images of potassium, phosphate, and boron and the whole spectrum showed the ratios of boron counts to total (%) as follows: control group: 1.35 ± 0.073%; 2hr boron exposure group: 2.33 ± 0.35%; and boron exposure/wash group: 1.58 ± 0.095%. Micro-beam PIXE/PIGE can be a promising tool for visualization of intracellular Boron.
Collapse
Affiliation(s)
- Kei Nakai
- Ibaraki Prefectural University of Health Sciences, 4669-2 Ami, Inashiki, Ibaraki, 300-0331, Japan; Department of Neurosurgery, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan; Department of Radiation Oncology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan.
| | - Keita Endo
- Department of Neurosurgery, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan
| | - Fumiyo Yoshida
- Department of Neurosurgery, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan
| | - Masashi Koka
- Takasaki Advanced Radiation Research Institute, National Institute for Quantum and Radiological Science and Technology, 1233 Watanuki, Takasaki, Gunma, 370-1292, Japan
| | - Naoto Yamada
- Takasaki Advanced Radiation Research Institute, National Institute for Quantum and Radiological Science and Technology, 1233 Watanuki, Takasaki, Gunma, 370-1292, Japan
| | - Takahiro Satoh
- Takasaki Advanced Radiation Research Institute, National Institute for Quantum and Radiological Science and Technology, 1233 Watanuki, Takasaki, Gunma, 370-1292, Japan
| | - Takao Tsurubuchi
- Department of Neurosurgery, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan.
| | - Akira Matsumura
- Department of Neurosurgery, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan
| | - Yoshitaka Matsumoto
- Department of Radiation Oncology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan
| | - Hideyuki Sakurai
- Department of Radiation Oncology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan
| |
Collapse
|
13
|
Tsygankova AR, Kanygin VV, Kasatova AI, Zav’yalov EL, Gusel’nikova TY, Kichigin AI, Mukhamadiyarov RA. Determination of boron by inductively coupled plasma atomic emission spectroscopy. Biodistribution of 10B in tumor-bearing mice. Russ Chem Bull 2020. [DOI: 10.1007/s11172-020-2805-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
14
|
Ono K, Tanaka H, Suzuki M. Reevaluation of CBE value of BPA for hepatocytes. Appl Radiat Isot 2020; 161:109159. [PMID: 32250845 DOI: 10.1016/j.apradiso.2020.109159] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2019] [Revised: 01/31/2020] [Accepted: 03/28/2020] [Indexed: 11/19/2022]
Abstract
The compound biological effectiveness (CBE) value of boronophenylalanine (BPA) for hepatocytes was experimentally determined for the purpose of boron neutron capture therapy (BNCT) for liver tumors. In this study, the critical reevaluation of previous value was performed. In previous experimental studies, the contribution of β component of dose was ignored in the response curve to X-ray. X-ray dose cell survival curves were estimated by combining the α/β values obtained in the ordinary micronucleus (MN) assay with the curve of MN-negative cell fraction (MN(-)F) to dose. This curve was compared to the boron neutron capture reaction (BNCR) dose curve. As a result, the CBE value was 4 at doses close to 0 Gy, decreasing to about 1.0 at doses close to 4.5 Gy. The new value is smaller than the previous value 4.2. This indicates that the bioequivalent dose to normal liver is lower than previously expected. Therefore, higher doses can be given to the tumor.
Collapse
Affiliation(s)
- Koji Ono
- Kansai BNCT Medical Center, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki-shi, Osaka, 569-8686, Japan.
| | - Hiroki Tanaka
- Radiation Oncology Research Center, Institute for Integrated Radiation and Nuclear Science Kyoto University (KURNS), 2 Asashiro-Nishi, Kumatori-cho, Osaka, 590-0494, Japan.
| | - Minoru Suzuki
- Radiation Oncology Research Center, Institute for Integrated Radiation and Nuclear Science Kyoto University (KURNS), 2 Asashiro-Nishi, Kumatori-cho, Osaka, 590-0494, Japan.
| |
Collapse
|
15
|
Nakamura S, Igaki H, Ito M, Okamoto H, Nishioka S, Iijima K, Nakayama H, Takemori M, Imamichi S, Kashihara T, Takahashi K, Inaba K, Okuma K, Murakami N, Abe Y, Nakayama Y, Masutani M, Nishio T, Itami J. Characterization of the relationship between neutron production and thermal load on a target material in an accelerator-based boron neutron capture therapy system employing a solid-state Li target. PLoS One 2019; 14:e0225587. [PMID: 31756237 PMCID: PMC6874357 DOI: 10.1371/journal.pone.0225587] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2019] [Accepted: 10/11/2019] [Indexed: 01/25/2023] Open
Abstract
An accelerator-based boron neutron capture therapy (BNCT) system that employs a solid-state Li target can achieve sufficient neutron flux derived from the 7Li(p,n) reaction. However, neutron production is complicated by the large thermal load expected on the target. The relationship between neutron production and thermal load was examined under various conditions. A target structure for neutron production consists of a Li target and a target basement. Four proton beam profiles were examined to vary the local thermal load on the target structure while maintaining a constant total thermal load. The efficiency of neutron production was evaluated with respect to the total number of protons delivered to the target structure. The target structure was also evaluated by observing its surface after certain numbers of protons were delivered. The yield of the sputtering effect was calculated via a Monte Carlo simulation to investigate whether it caused complications in neutron production. The efficiency of neutron production and the amount of damage done depended on the proton profile. A more focused proton profile resulted in greater damage. The efficiency decreased as the total number of protons delivered to the target structure increased, and the rate of decrease depended on the proton profile. The sputtering effect was not sufficiently large to be a main factor in the reduction in neutron production. The proton beam profile on the target structure was found to be important to the stable operation of the system with a solid-state Li target. The main factor in the rate of reduction in neutron production was found to be the local thermal load induced by proton irradiation of the target.
Collapse
Affiliation(s)
- Satoshi Nakamura
- Department of Medical Physics, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
- Division of Research and Development for Boron Neutron Capture Therapy, National Cancer Center Exploratory Oncology Research & Clinical Trial Center, Chuo-ku, Tokyo, Japan
| | - Hiroshi Igaki
- Division of Research and Development for Boron Neutron Capture Therapy, National Cancer Center Exploratory Oncology Research & Clinical Trial Center, Chuo-ku, Tokyo, Japan
- Department of Radiation Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
- * E-mail:
| | - Masashi Ito
- Department of Radiology, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
| | - Hiroyuki Okamoto
- Department of Medical Physics, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
- Division of Research and Development for Boron Neutron Capture Therapy, National Cancer Center Exploratory Oncology Research & Clinical Trial Center, Chuo-ku, Tokyo, Japan
| | - Shie Nishioka
- Department of Medical Physics, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
- Division of Research and Development for Boron Neutron Capture Therapy, National Cancer Center Exploratory Oncology Research & Clinical Trial Center, Chuo-ku, Tokyo, Japan
| | - Kotaro Iijima
- Department of Medical Physics, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
| | - Hiroki Nakayama
- Department of Medical Physics, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
- Department of Radiological Science, Graduate School of Human Health Sciences, Arakawa-ku, Tokyo, Japan
| | - Mihiro Takemori
- Department of Medical Physics, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
- Department of Radiological Science, Graduate School of Human Health Sciences, Arakawa-ku, Tokyo, Japan
| | - Shoji Imamichi
- Division of Research and Development for Boron Neutron Capture Therapy, National Cancer Center Exploratory Oncology Research & Clinical Trial Center, Chuo-ku, Tokyo, Japan
- Lab of Collaborative Research, Division of Cellular Signaling, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan
| | - Tairo Kashihara
- Department of Radiation Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
| | - Kana Takahashi
- Department of Radiation Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
| | - Koji Inaba
- Department of Radiation Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
| | - Kae Okuma
- Department of Radiation Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
| | - Naoya Murakami
- Department of Radiation Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
| | - Yoshihisa Abe
- Division of Research and Development for Boron Neutron Capture Therapy, National Cancer Center Exploratory Oncology Research & Clinical Trial Center, Chuo-ku, Tokyo, Japan
- Department of Radiological Technology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
| | - Yuko Nakayama
- Department of Radiation Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
| | - Mitsuko Masutani
- Division of Research and Development for Boron Neutron Capture Therapy, National Cancer Center Exploratory Oncology Research & Clinical Trial Center, Chuo-ku, Tokyo, Japan
- Lab of Collaborative Research, Division of Cellular Signaling, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan
- Center for Bioinformatics and Molecular Medicine, Department of Frontier Life Sciences, Nagasaki University Graduate School of Biomedical Sciences, Sakamoto, Nagasaki, Japan
| | - Teiji Nishio
- Department of Medical Physics, Graduate School of Medicine, Tokyo Women’s Medical University, Shinjuku-ku, Tokyo, Japan
| | - Jun Itami
- Department of Medical Physics, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
- Division of Research and Development for Boron Neutron Capture Therapy, National Cancer Center Exploratory Oncology Research & Clinical Trial Center, Chuo-ku, Tokyo, Japan
- Department of Radiation Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
| |
Collapse
|
16
|
Kanemitsu T, Kawabata S, Fukumura M, Futamura G, Hiramatsu R, Nonoguchi N, Nakagawa F, Takata T, Tanaka H, Suzuki M, Masunaga SI, Ono K, Miyatake SI, Nakamura H, Kuroiwa T. Folate receptor-targeted novel boron compound for boron neutron capture therapy on F98 glioma-bearing rats. RADIATION AND ENVIRONMENTAL BIOPHYSICS 2019; 58:59-67. [PMID: 30474719 DOI: 10.1007/s00411-018-0765-2] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/17/2018] [Accepted: 11/12/2018] [Indexed: 06/09/2023]
Abstract
Folic acid (FA) has high affinity for the folate receptor (FR), which is limited expressed in normal human tissues, but over-expressed in several tumor cells, including glioblastoma cells. In the present work, a novel pteroyl-closo-dodecaborate conjugate (PBC) was developed, in which the pteroyl group interacts with FR, and the efficacy of boron neutron capture therapy (BNCT) using PBC was investigated. Thus, in vitro and in vivo studies were performed using F98 rat glioma cells and F98 glioma-bearing rats. For the in vivo study, boronophenylalanine (BPA) was intravenously administered, while PBC was administered by convection-enhanced delivery (CED)-a method for direct local drug infusion into the brain of rats. Furthermore, a combination of PBC administered by CED and BPA administered by intravenous (i.v.) injection was also investigated. In the biodistribution experiment, PBC administration at 6 h after CED termination showed the highest cellular boron concentrations (64.6 ± 29.6 µg B/g). Median survival time (MST) of untreated controls was 23.0 days (range 21-24 days). MST of rats administered PBC (CED) followed by neutron irradiation was 31 days (range 26-36 days), which was similar to that of rats administered i.v. BPA (30 days; range 25-37 days). Moreover, the combination group [PBC (CED) and i.v. BPA] showed the longest MST (38 days; range 28-40 days). It is concluded that a significant MST increase was noted in the survival time of the combination group of PBC (CED) and i.v. BPA compared to that in the single-boron agent groups. These findings suggest that the combination use of PBC (CED) has additional effects.
Collapse
Affiliation(s)
- Takuya Kanemitsu
- Department of Neurosurgery, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki City, Osaka, 569-8686, Japan
| | - Shinji Kawabata
- Department of Neurosurgery, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki City, Osaka, 569-8686, Japan.
| | - Masao Fukumura
- Department of Neurosurgery, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki City, Osaka, 569-8686, Japan
| | - Gen Futamura
- Department of Neurosurgery, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki City, Osaka, 569-8686, Japan
| | - Ryo Hiramatsu
- Department of Neurosurgery, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki City, Osaka, 569-8686, Japan
| | - Naosuke Nonoguchi
- Department of Neurosurgery, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki City, Osaka, 569-8686, Japan
| | - Fumiko Nakagawa
- Laboratory for Chemistry and Life Science, Institute of Innovative Research Tokyo Institute of Technology, 4259 Nagatsuta-cho, Midori-ku, Yokohama, 226-8503, Japan
| | - Takushi Takata
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2 Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka, 590-0494, Japan
| | - Hiroki Tanaka
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2 Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka, 590-0494, Japan
| | - Minoru Suzuki
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2 Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka, 590-0494, Japan
| | - Shin-Ichiro Masunaga
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2 Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka, 590-0494, Japan
| | - Koji Ono
- Kansai BNCT Medical Center, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki City, Osaka, 569-8686, Japan
| | - Shin-Ichi Miyatake
- Section for Advanced Medical Development, Cancer Center, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki City, Osaka, 569-8686, Japan
| | - Hiroyuki Nakamura
- Laboratory for Chemistry and Life Science, Institute of Innovative Research Tokyo Institute of Technology, 4259 Nagatsuta-cho, Midori-ku, Yokohama, 226-8503, Japan
| | - Toshihiko Kuroiwa
- Department of Neurosurgery, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki City, Osaka, 569-8686, Japan
| |
Collapse
|
17
|
Safavi-Naeini M, Chacon A, Guatelli S, Franklin DR, Bambery K, Gregoire MC, Rosenfeld A. Opportunistic dose amplification for proton and carbon ion therapy via capture of internally generated thermal neutrons. Sci Rep 2018; 8:16257. [PMID: 30390002 PMCID: PMC6215016 DOI: 10.1038/s41598-018-34643-w] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2018] [Accepted: 10/22/2018] [Indexed: 12/11/2022] Open
Abstract
This paper presents Neutron Capture Enhanced Particle Therapy (NCEPT), a method for enhancing the radiation dose delivered to a tumour relative to surrounding healthy tissues during proton and carbon ion therapy by capturing thermal neutrons produced inside the treatment volume during irradiation. NCEPT utilises extant and in-development boron-10 and gadolinium-157-based drugs from the related field of neutron capture therapy. Using Monte Carlo simulations, we demonstrate that a typical proton or carbon ion therapy treatment plan generates an approximately uniform thermal neutron field within the target volume, centred around the beam path. The tissue concentrations of neutron capture agents required to obtain an arbitrary 10% increase in biological effective dose are estimated for realistic treatment plans, and compared to concentrations previously reported in the literature. We conclude that the proposed method is theoretically feasible, and can provide a worthwhile improvement in the dose delivered to the tumour relative to healthy tissue with readily achievable concentrations of neutron capture enhancement drugs.
Collapse
Affiliation(s)
- Mitra Safavi-Naeini
- Australian Nuclear Science and Technology Organisation (ANSTO), Sydney, Australia.
- Centre for Medical Radiation Physics, University of Wollongong, Sydney, Australia.
| | - Andrew Chacon
- Australian Nuclear Science and Technology Organisation (ANSTO), Sydney, Australia
- Centre for Medical Radiation Physics, University of Wollongong, Sydney, Australia
| | - Susanna Guatelli
- Centre for Medical Radiation Physics, University of Wollongong, Sydney, Australia
| | - Daniel R Franklin
- Faculty of Engineering & IT, University of Technology Sydney, Sydney, Australia
| | - Keith Bambery
- Australian Nuclear Science and Technology Organisation (ANSTO), Sydney, Australia
| | - Marie-Claude Gregoire
- Australian Nuclear Science and Technology Organisation (ANSTO), Sydney, Australia
- Centre for Medical Radiation Physics, University of Wollongong, Sydney, Australia
| | - Anatoly Rosenfeld
- Centre for Medical Radiation Physics, University of Wollongong, Sydney, Australia
| |
Collapse
|
18
|
NAKAMURA S, IMAMICHI S, MASUMOTO K, ITO M, WAKITA A, OKAMOTO H, NISHIOKA S, IIJIMA K, KOBAYASHI K, ABE Y, IGAKI H, KURITA K, NISHIO T, MASUTANI M, ITAMI J. Evaluation of radioactivity in the bodies of mice induced by neutron exposure from an epi-thermal neutron source of an accelerator-based boron neutron capture therapy system. PROCEEDINGS OF THE JAPAN ACADEMY. SERIES B, PHYSICAL AND BIOLOGICAL SCIENCES 2017; 93:821-831. [PMID: 29225308 PMCID: PMC5790759 DOI: 10.2183/pjab.93.051] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 05/26/2017] [Accepted: 09/08/2017] [Indexed: 06/07/2023]
Abstract
This study aimed to evaluate the residual radioactivity in mice induced by neutron irradiation with an accelerator-based boron neutron capture therapy (BNCT) system using a solid Li target. The radionuclides and their activities were evaluated using a high-purity germanium (HP-Ge) detector. The saturated radioactivity of the irradiated mouse was estimated to assess the radiation protection needs for using the accelerator-based BNCT system. 24Na, 38Cl, 80mBr, 82Br, 56Mn, and 42K were identified, and their saturated radioactivities were (1.4 ± 0.1) × 102, (2.2 ± 0.1) × 101, (3.4 ± 0.4) × 102, 2.8 ± 0.1, 8.0 ± 0.1, and (3.8 ± 0.1) × 101 Bq/g/mA, respectively. The 24Na activation rate at a given neutron fluence was found to be consistent with the value reported from nuclear-reactor-based BNCT experiments. The induced activity of each nuclide can be estimated by entering the saturated activity of each nuclide, sample mass, irradiation time, and proton current into the derived activation equation in our accelerator-based BNCT system.
Collapse
Affiliation(s)
- Satoshi NAKAMURA
- Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan
- Department of Physics, Rikkyo University, Tokyo, Japan
- Division of Research and Development for boron neutron capture therapy, National Cancer Center Exploratory Oncology Research & Clinical Trial Center, Tokyo, Japan
| | - Shoji IMAMICHI
- Division of Research and Development for boron neutron capture therapy, National Cancer Center Exploratory Oncology Research & Clinical Trial Center, Tokyo, Japan
- Division of Genetics, National Cancer Center Research Institute, Tokyo, Japan
| | | | - Masashi ITO
- Division of Research and Development for boron neutron capture therapy, National Cancer Center Exploratory Oncology Research & Clinical Trial Center, Tokyo, Japan
- Department of Radiological Technology, National Cancer Center Hospital, Tokyo, Japan
| | - Akihisa WAKITA
- Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan
- Division of Research and Development for boron neutron capture therapy, National Cancer Center Exploratory Oncology Research & Clinical Trial Center, Tokyo, Japan
| | - Hiroyuki OKAMOTO
- Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan
- Division of Research and Development for boron neutron capture therapy, National Cancer Center Exploratory Oncology Research & Clinical Trial Center, Tokyo, Japan
| | - Shie NISHIOKA
- Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan
- Division of Research and Development for boron neutron capture therapy, National Cancer Center Exploratory Oncology Research & Clinical Trial Center, Tokyo, Japan
| | - Kotaro IIJIMA
- Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - Kazuma KOBAYASHI
- Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan
- Division of Research and Development for boron neutron capture therapy, National Cancer Center Exploratory Oncology Research & Clinical Trial Center, Tokyo, Japan
| | - Yoshihisa ABE
- Division of Research and Development for boron neutron capture therapy, National Cancer Center Exploratory Oncology Research & Clinical Trial Center, Tokyo, Japan
- Department of Radiological Technology, National Cancer Center Hospital, Tokyo, Japan
| | - Hiroshi IGAKI
- Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan
- Division of Research and Development for boron neutron capture therapy, National Cancer Center Exploratory Oncology Research & Clinical Trial Center, Tokyo, Japan
| | | | - Teiji NISHIO
- Department of Medical Physics, Graduate School of Medicine, Tokyo Women’s University, Tokyo, Japan
| | - Mitsuko MASUTANI
- Division of Research and Development for boron neutron capture therapy, National Cancer Center Exploratory Oncology Research & Clinical Trial Center, Tokyo, Japan
- Division of Genetics, National Cancer Center Research Institute, Tokyo, Japan
- Department of Frontier Life Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - Jun ITAMI
- Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan
- Division of Research and Development for boron neutron capture therapy, National Cancer Center Exploratory Oncology Research & Clinical Trial Center, Tokyo, Japan
| |
Collapse
|
19
|
Ono K. An analysis of the structure of the compound biological effectiveness factor. JOURNAL OF RADIATION RESEARCH 2016; 57 Suppl 1:i83-i89. [PMID: 27021218 PMCID: PMC4990111 DOI: 10.1093/jrr/rrw022] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/14/2023]
Abstract
This report is an analysis of the structure of the compound biological effectiveness (CBE) factor. The value of the CBE factor previously reported was revalued for the central nervous system, skin and lung. To describe the structure, the following terms are introduced: the vascular CBE (v-CBE), intraluminal CBE (il-CBE), extraluminal CBE (el-CBE) and non-vascular CBE (nv-CBE) factors and the geometric biological factor (GBF), i.e. the contributions that are derived from the total dose to the vasculature, each dose to vasculature from the intraluminal side and the extraluminal side, the dose to the non-vascular tissue and the factor to calculate el-CBE from il-CBE, respectively. The el-CBE factor element was also introduced to relate il-CBE to el-CBE factors. A CBE factor of 0.36 for disodium mercaptoundecahydrododecaborate (BSH) for the CNS was independent of the (10)B level in the blood; however, that for p-Boron-L-phenylalanine (BPA) increased with the (10)B level ratio of the normal tissue to the blood (N/B). The CBE factor was expressed as follows: factor = 0.32 + N/B × 1.65. The factor of 0.32 at 0 of N/B was close to the CBE factor for BSH. GBFs had similar values, between BSH and BPA, 1.39 and 1.52, respectively. The structure of the CBE factor for BPA to the lung was also elucidated based on this idea. The factor is described as follows: CBE factor = 0.32 + N/B × 1.80. By this elucidation of the structure of the CBE factor, it is expected that basic and clinical research into boron neutron capture therapy will progress.
Collapse
Affiliation(s)
- Koji Ono
- Research Division of Advanced Neutron Therapy, Particle Radiation Oncology Research Center, Kyoto University Research Reactor Institute, 2-1010, Asashironishi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan
| |
Collapse
|
20
|
Hiramatsu R, Kawabata S, Tanaka H, Sakurai Y, Suzuki M, Ono K, Miyatake SI, Kuroiwa T, Hao E, Vicente MGH. Tetrakis(p-Carboranylthio-Tetrafluorophenyl)Chlorin (TPFC): Application for Photodynamic Therapy and Boron Neutron Capture Therapy. J Pharm Sci 2016; 104:962-970. [PMID: 28756849 DOI: 10.1002/jps.24317] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2014] [Revised: 11/24/2014] [Accepted: 12/02/2014] [Indexed: 11/06/2022]
Abstract
Carboranyl-containing chlorins have emerged as promising dual sensitizers for use in both photodynamic therapy (PDT) and boron neutron capture therapy (BNCT), by virtue of their known tumor affinity, low cytotoxicity in dark conditions, and their strong absorptions in the red region of the optical spectrum. Tetrakis(p-carboranylthio-tetrafluorophenyl)chlorin (TPFC) is a new synthetic carboranyl-containing chlorin of high boron content (24% by weight). To evaluate TPFC's applicability as sensitizer for both PDT and BNCT, we performed an in vitro and in vivo study using F98 rat glioma cells and F98 rat glioma-bearing brain tumor models. For the in vivo BNCT study, we used boronophenylalanine (BPA), which is currently used in clinical BNCT studies, via intravenous administration (i.v.) and/or used TPFC via convection-enhanced delivery (CED), a method for local drug infusion directly into the brain. In the in vitro PDT study, the cell surviving fraction following laser irradiation (9J/cm2) was 0.035 whereas in the in vitro BNCT study, the cell surviving fraction following neutron irradiation (thermal neutron=1.73×1012 n/cm2) was 0.04. In the in vivo BNCT study, the median survival time following concomitant administration of BPA (i.v.) and TPFC (CED) was 42days (95% confidence interval; 37-43days). © 2014 Wiley Periodicals, Inc. and the American Pharmacists Association.
Collapse
Affiliation(s)
- Ryo Hiramatsu
- Department of Neurosurgery, Osaka Medical College, Osaka, Japan 569-8686
| | - Shinji Kawabata
- Department of Neurosurgery, Osaka Medical College, Osaka, Japan 569-8686.
| | - Hiroki Tanaka
- Kyoto University Research Reactor Institue, Kumatori, Osaka, Japan 590-0494
| | - Yoshinori Sakurai
- Kyoto University Research Reactor Institue, Kumatori, Osaka, Japan 590-0494
| | - Minoru Suzuki
- Kyoto University Research Reactor Institue, Kumatori, Osaka, Japan 590-0494
| | - Koji Ono
- Kyoto University Research Reactor Institue, Kumatori, Osaka, Japan 590-0494
| | - Shin-Ichi Miyatake
- Department of Neurosurgery, Osaka Medical College, Osaka, Japan 569-8686
| | - Toshihiko Kuroiwa
- Department of Neurosurgery, Osaka Medical College, Osaka, Japan 569-8686
| | - Erhong Hao
- Department of Chemistry, Louisiana State University, Baton Rouge, Louisiana 70803
| | - M Graça H Vicente
- Department of Chemistry, Louisiana State University, Baton Rouge, Louisiana 70803
| |
Collapse
|
21
|
Autoradiographic and histopathological studies of boric acid-mediated BNCT in hepatic VX2 tumor-bearing rabbits: Specific boron retention and damage in tumor and tumor vessels. Appl Radiat Isot 2015; 106:176-80. [DOI: 10.1016/j.apradiso.2015.08.034] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2015] [Revised: 08/07/2015] [Accepted: 08/25/2015] [Indexed: 11/18/2022]
|
22
|
Rossini AE, Dagrosa MA, Portu A, Saint Martin G, Thorp S, Casal M, Navarro A, Juvenal GJ, Pisarev MA. Assessment of biological effectiveness of boron neutron capture therapy in primary and metastatic melanoma cell lines. Int J Radiat Biol 2014; 91:81-9. [DOI: 10.3109/09553002.2014.942013] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
23
|
Yanagie H, Higashi S, Seguchi K, Ikushima I, Fujihara M, Nonaka Y, Oyama K, Maruyama S, Hatae R, Suzuki M, Masunaga SI, Kinashi T, Sakurai Y, Tanaka H, Kondo N, Narabayashi M, Kajiyama T, Maruhashi A, Ono K, Nakajima J, Ono M, Takahashi H, Eriguchi M. Pilot clinical study of boron neutron capture therapy for recurrent hepatic cancer involving the intra-arterial injection of a (10)BSH-containing WOW emulsion. Appl Radiat Isot 2014; 88:32-7. [PMID: 24559940 DOI: 10.1016/j.apradiso.2014.01.014] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2012] [Revised: 01/16/2014] [Accepted: 01/16/2014] [Indexed: 10/25/2022]
Abstract
A 63-year-old man with multiple HCC in his left liver lobe was enrolled as the first patient in a pilot study of boron neutron capture therapy (BNCT) involving the selective intra-arterial infusion of a (10)BSH-containing water-in-oil-in-water emulsion ((10)BSH-WOW). The size of the tumorous region remained stable during the 3 months after the BNCT. No adverse effects of the BNCT were observed. The present results show that (10)BSH-WOW can be used as novel intra-arterial boron carriers during BNCT for HCC.
Collapse
Affiliation(s)
- Hironobu Yanagie
- Department of Innovative Cancer Therapeutics: Alpha particle and Immuno-therapeutics, Meiji Pharmaceutical University, 2-522-1 Noshio, Kiyose, Tokyo 204-8588, Japan; Department of Nuclear Engineering & Management, Graduate School of Engineering, The University of Tokyo, Japan; Cooperative Unit of Medicine & Engineering, The University of Tokyo Hospital, Tokyo, Japan.
| | - Syushi Higashi
- Department of Surgery, Kojin-kai Medical City East Hospital, Miyazaki, Japan
| | - Koji Seguchi
- Department of Surgery, Kojin-kai Medical City East Hospital, Miyazaki, Japan
| | - Ichiro Ikushima
- Department of Innovative Cancer Therapeutics: Alpha particle and Immuno-therapeutics, Meiji Pharmaceutical University, 2-522-1 Noshio, Kiyose, Tokyo 204-8588, Japan; Kyushu Medical & Industrial Sources Foundation, Miyazaki, Japan; Department of Radiology, Miyakonojyo Metropolitan Hospital, Miyazaki, Japan
| | | | | | - Kazuyuki Oyama
- Department of Radiology, Shin-Yamate Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan
| | - Syoji Maruyama
- Department of Surgery, Shin-Yamate Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan
| | - Ryo Hatae
- Department of Surgery, Shin-Yamate Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan
| | - Minoru Suzuki
- Research Reactor Institute, Kyoto University, Osaka, Japan
| | | | - Tomoko Kinashi
- Research Reactor Institute, Kyoto University, Osaka, Japan
| | | | - Hiroki Tanaka
- Research Reactor Institute, Kyoto University, Osaka, Japan
| | - Natsuko Kondo
- Research Reactor Institute, Kyoto University, Osaka, Japan
| | | | - Tetsuya Kajiyama
- Department of Innovative Cancer Therapeutics: Alpha particle and Immuno-therapeutics, Meiji Pharmaceutical University, 2-522-1 Noshio, Kiyose, Tokyo 204-8588, Japan
| | | | - Koji Ono
- Research Reactor Institute, Kyoto University, Osaka, Japan
| | - Jun Nakajima
- Cooperative Unit of Medicine & Engineering, The University of Tokyo Hospital, Tokyo, Japan; Department of Respiratory Surgery, The University of Tokyo Hospital, Tokyo, Japan
| | - Minoru Ono
- Cooperative Unit of Medicine & Engineering, The University of Tokyo Hospital, Tokyo, Japan; Department of Cardiac Surgery, The University of Tokyo Hospital, Tokyo, Japan
| | - Hiroyuki Takahashi
- Department of Nuclear Engineering & Management, Graduate School of Engineering, The University of Tokyo, Japan; Cooperative Unit of Medicine & Engineering, The University of Tokyo Hospital, Tokyo, Japan
| | - Masazumi Eriguchi
- Department of Surgery, Shin-Yamate Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan
| |
Collapse
|
24
|
Pozzi ECC, Trivillin VA, Colombo LL, Monti Hughes A, Thorp SI, Cardoso JE, Garabalino MA, Molinari AJ, Heber EM, Curotto P, Miller M, Itoiz ME, Aromando RF, Nigg DW, Schwint AE. Boron neutron capture therapy (BNCT) for liver metastasis in an experimental model: dose–response at five-week follow-up based on retrospective dose assessment in individual rats. RADIATION AND ENVIRONMENTAL BIOPHYSICS 2013; 52:481-491. [PMID: 24077963 DOI: 10.1007/s00411-013-0490-9] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/26/2013] [Accepted: 08/24/2013] [Indexed: 06/02/2023]
Abstract
Boron neutron capture therapy (BNCT) was proposed for untreatable colorectal liver metastases. Employing an experimental model of liver metastases in rats, we recently demonstrated that BNCT mediated by boronophenylalanine (BPA-BNCT) at 13 Gy prescribed to tumor is therapeutically useful at 3-week follow-up. The aim of the present study was to evaluate dose–response at 5-week follow-up, based on retrospective dose assessment in individual rats. BDIX rats were inoculated with syngeneic colon cancer cells DHD/K12/TRb. Tumor-bearing animals were divided into three groups: BPA-BNCT (n = 19), Beam only (n = 8) and Sham (n = 7) (matched manipulation, no treatment). For each rat, neutron flux was measured in situ and boron content was measured in a pre-irradiation blood sample for retrospective individual dose assessment. For statistical analysis (ANOVA), individual data for the BPA-BNCT group were pooled according to absorbed tumor dose, BPA-BNCT I: 4.5–8.9 Gy and BPA-BNCT II: 9.2–16 Gy. At 5 weeks post-irradiation, the tumor surface area post-treatment/pre-treatment ratio was 12.2 ± 6.6 for Sham, 7.8 ± 4.1 for Beam only, 4.4 ± 5.6 for BPA-BNCT I and 0.45 ± 0.20 for BPA-BNCT II; tumor nodule weight was 750 ± 480 mg for Sham, 960 ± 620 mg for Beam only, 380 ± 720 mg for BPA-BNCT I and 7.3 ± 5.9 mg for BPA-BNCT II. The BPA-BNCT II group exhibited statistically significant tumor control with no contributory liver toxicity. Potential threshold doses for tumor response and significant tumor control were established at 6.1 and 9.2 Gy, respectively.
Collapse
|
25
|
Evaluation of performance of an accelerator-based BNCT facility for the treatment of different tumor targets. Phys Med 2013; 29:436-46. [PMID: 23462279 DOI: 10.1016/j.ejmp.2013.01.006] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/19/2012] [Revised: 01/24/2013] [Accepted: 01/28/2013] [Indexed: 11/21/2022] Open
Abstract
PURPOSE Encouraging Boron Neutron Capture Therapy (BNCT) clinical results obtained in recent years have stimulated intense research to develop accelerator-based neutron sources to be installed in clinical facilities. In this work an assessment of an accelerator-based BNCT facility for the treatment of different tumor targets was performed, comparing the accelerator-derived results with reported reactor-based trials under similar conditions and subjected to the same clinical protocols. MATERIALS AND METHODS A set of real image studies was used to cover clinical-like cases of brain and head-and-neck tumors. In addition, two clinical cases of malignant nodular melanoma treated at the RA-6 BNCT facility in Argentina were used to thoroughly compare the clinical dosimetry with the accelerator-derived results. RESULTS The minimum weighted dose delivered to the clinical target volume was higher than 30 Gy and 14 Gy for the brain tumor and head-and-neck cases, respectively, in agreement with those achieved in clinical applications. For the melanoma cases, the minimum tumor doses were equal or higher than those achieved with the RA-6 reactor for identical field orientation and protocol. The whole-body dose assessment showed that the maximum photon-equivalent doses for those normal organs close to the beam direction were below the upper limits considered in the protocols used in the present work. CONCLUSIONS The obtained results indicate not only the good performance of the proposed beam shaping assembly design associated to the facility but also the potential applicability of accelerator-based BNCT in the treatment of both superficial and deep-seated tumors.
Collapse
|
26
|
Pozzi ECC, Cardoso JE, Colombo LL, Thorp S, Monti Hughes A, Molinari AJ, Garabalino MA, Heber EM, Miller M, Itoiz ME, Aromando RF, Nigg DW, Quintana J, Trivillin VA, Schwint AE. Boron neutron capture therapy (BNCT) for liver metastasis: therapeutic efficacy in an experimental model. RADIATION AND ENVIRONMENTAL BIOPHYSICS 2012; 51:331-339. [PMID: 22544068 DOI: 10.1007/s00411-012-0419-8] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/08/2012] [Accepted: 04/14/2012] [Indexed: 05/31/2023]
Abstract
Boron neutron capture therapy (BNCT) was proposed for untreatable colorectal liver metastases. The present study evaluates tumor control and potential radiotoxicity of BNCT in an experimental model of liver metastasis. BDIX rats were inoculated with syngeneic colon cancer cells DHD/K12/TRb. Tumor-bearing animals were divided into three groups: BPA-BNCT, boronophenylalanine (BPA) + neutron irradiation; Beam only, neutron irradiation; Sham, matched manipulation. The total absorbed dose administered with BPA-BNCT was 13 ± 3 Gy in tumor and 9 ± 2 Gy in healthy liver. Three weeks post-treatment, the tumor surface area post-treatment/pre-treatment ratio was 0.46 ± 0.20 for BPA-BNCT, 2.7 ± 1.8 for Beam only and 4.5 ± 3.1 for Sham. The pre-treatment tumor nodule mass of 48 ± 19 mg fell significantly to 19 ± 16 mg for BPA-BNCT, but rose significantly to 140 ± 106 mg for Beam only and to 346 ± 302 mg for Sham. For both end points, the differences between the BPA-BNCT group and each of the other groups were statistically significant (ANOVA). No clinical, macroscopic or histological normal liver radiotoxicity was observed. It is concluded that BPA-BNCT induced a significant remission of experimental colorectal tumor nodules in liver with no contributory liver toxicity.
Collapse
Affiliation(s)
- Emiliano C C Pozzi
- Department Radiobiology, National Atomic Energy Commission, Avenida General Paz 1499, B1650KNA, San Martin, Province Buenos Aires, Argentina
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Horiguchi H, Nakamura T, Kumada H, Yanagie H, Suzuki M, Sagawa H. Investigation of irradiation conditions for recurrent breast cancer in JRR-4. Appl Radiat Isot 2011; 69:1882-4. [DOI: 10.1016/j.apradiso.2011.03.036] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2010] [Revised: 03/22/2011] [Accepted: 03/24/2011] [Indexed: 10/18/2022]
|
28
|
Feasibility evaluation of neutron capture therapy for hepatocellular carcinoma using selective enhancement of boron accumulation in tumour with intra-arterial administration of boron-entrapped water-in-oil-in-water emulsion. Appl Radiat Isot 2011; 69:1854-7. [DOI: 10.1016/j.apradiso.2011.04.022] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2010] [Revised: 04/16/2011] [Accepted: 04/18/2011] [Indexed: 11/24/2022]
|
29
|
Fujii H, Matsuyama A, Komoda H, Sasai M, Suzuki M, Asano T, Doki Y, Kirihata M, Ono K, Tabata Y, Kaneda Y, Sawa Y, Lee CM. Cationized gelatin-HVJ envelope with sodium borocaptate improved the BNCT efficacy for liver tumors in vivo. Radiat Oncol 2011; 6:8. [PMID: 21247507 PMCID: PMC3035588 DOI: 10.1186/1748-717x-6-8] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2010] [Accepted: 01/20/2011] [Indexed: 11/21/2022] Open
Abstract
BACKGROUND Boron neutron capture therapy (BNCT) is a cell-selective radiation therapy that uses the alpha particles and lithium nuclei produced by the boron neutron capture reaction. BNCT is a relatively safe tool for treating multiple or diffuse malignant tumors with little injury to normal tissue. The success or failure of BNCT depends upon the 10B compound accumulation within tumor cells and the proximity of the tumor cells to the body surface. To extend the therapeutic use of BNCT from surface tumors to visceral tumors will require 10B compounds that accumulate strongly in tumor cells without significant accumulation in normal cells, and an appropriate delivery method for deeper tissues.Hemagglutinating Virus of Japan Envelope (HVJ-E) is used as a vehicle for gene delivery because of its high ability to fuse with cells. However, its strong hemagglutination activity makes HVJ-E unsuitable for systemic administration.In this study, we developed a novel vector for 10B (sodium borocaptate: BSH) delivery using HVJ-E and cationized gelatin for treating multiple liver tumors with BNCT without severe adverse events. METHODS We developed cationized gelatin conjugate HVJ-E combined with BSH (CG-HVJ-E-BSH), and evaluated its characteristics (toxicity, affinity for tumor cells, accumulation and retention in tumor cells, boron-carrying capacity to multiple liver tumors in vivo, and bio-distribution) and effectiveness in BNCT therapy in a murine model of multiple liver tumors. RESULTS CG-HVJ-E reduced hemagglutination activity by half and was significantly less toxic in mice than HVJ-E. Higher 10B concentrations in murine osteosarcoma cells (LM8G5) were achieved with CG-HVJ-E-BSH than with BSH. When administered into mice bearing multiple LM8G5 liver tumors, the tumor/normal liver ratios of CG-HVJ-E-BSH were significantly higher than those of BSH for the first 48 hours (p < 0.05). In suppressing the spread of tumor cells in mice, BNCT treatment was as effective with CG-HVJ-E-BSH as with BSH containing a 35-fold higher 10B dose. Furthermore, CG-HVJ-E-BSH significantly increased the survival time of tumor-bearing mice compared to BSH at a comparable dosage of 10B. CONCLUSION CG-HVJ-E-BSH is a promising strategy for the BNCT treatment of visceral tumors without severe adverse events to surrounding normal tissues.
Collapse
Affiliation(s)
- Hitoshi Fujii
- Department of Surgery, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Akifumi Matsuyama
- Medical Center for Translational Research, Osaka University Hospital, Osaka, Japan
| | - Hiroshi Komoda
- Department of Surgery, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Masao Sasai
- Medical Center for Translational Research, Osaka University Hospital, Osaka, Japan
| | - Minoru Suzuki
- Particle Radiation Oncology Research Center Laboratory, Research Reactor Institute, Kyoto University, Osaka, Japan
| | - Tomoyuki Asano
- Department of Agriculture, Osaka Prefectural University, Osaka, Japan
| | - Yuichiro Doki
- Department of Surgery, Osaka University Graduate School of Medicine, Osaka, Japan
| | | | - Koji Ono
- Particle Radiation Oncology Research Center Laboratory, Research Reactor Institute, Kyoto University, Osaka, Japan
| | - Yasuhiko Tabata
- Department of Biomaterials, Institute for Frontier Medical Sciences, Kyoto University, Kyoto, Japan
| | - Yasufumi Kaneda
- Division of Gene Therapy Science, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Yoshiki Sawa
- Department of Surgery, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Chun Man Lee
- Department of Surgery, Osaka University Graduate School of Medicine, Osaka, Japan
- Medical Center for Translational Research, Osaka University Hospital, Osaka, Japan
- Health Care Economics and Industrial Policy, Osaka University Graduate School of Medicine, Osaka Japan
| |
Collapse
|
30
|
Dagrosa MA, Crivello M, Perona M, Thorp S, Santa Cruz GA, Pozzi E, Casal M, Thomasz L, Cabrini R, Kahl S, Juvenal GJ, Pisarev MA. First evaluation of the biologic effectiveness factors of boron neutron capture therapy (BNCT) in a human colon carcinoma cell line. Int J Radiat Oncol Biol Phys 2011; 79:262-8. [PMID: 20932650 DOI: 10.1016/j.ijrobp.2010.07.020] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2010] [Revised: 06/27/2010] [Accepted: 07/07/2010] [Indexed: 11/16/2022]
Abstract
PURPOSE DNA lesions produced by boron neutron capture therapy (BNCT) and those produced by gamma radiation in a colon carcinoma cell line were analyzed. We have also derived the relative biologic effectiveness factor (RBE) of the neutron beam of the RA-3- Argentine nuclear reactor, and the compound biologic effectiveness (CBE) values for p-boronophenylalanine ((10)BPA) and for 2,4-bis (α,β-dihydroxyethyl)-deutero-porphyrin IX ((10)BOPP). METHODS AND MATERIALS Exponentially growing human colon carcinoma cells (ARO81-1) were distributed into the following groups: (1) BPA (10 ppm (10)B) + neutrons, (2) BOPP (10 ppm (10)B) + neutrons, (3) neutrons alone, and (4) gamma rays ((60)Co source at 1 Gy/min dose-rate). Different irradiation times were used to obtain total absorbed doses between 0.3 and 5 Gy (±10%) (thermal neutrons flux = 7.5 10(9) n/cm(2) sec). RESULTS The frequency of micronucleated binucleated cells and the number of micronuclei per micronucleated binucleated cells showed a dose-dependent increase until approximately 2 Gy. The response to gamma rays was significantly lower than the response to the other treatments (p < 0.05). The irradiations with neutrons alone and neutrons + BOPP showed curves that did not differ significantly from, and showed less DNA damage than, irradiation with neutrons + BPA. A decrease in the surviving fraction measured by 3-(4,5-dimetiltiazol-2-il)-2,5-difeniltetrazolium bromide (MTT) assay as a function of the absorbed dose was observed for all the treatments. The RBE and CBE factors calculated from cytokinesis block micronucleus (CBMN) and MTT assays were, respectively, the following: beam RBE: 4.4 ± 1.1 and 2.4 ± 0.6; CBE for BOPP: 8.0 ± 2.2 and 2.0 ± 1; CBE for BPA: 19.6 ± 3.7 and 3.5 ± 1.3. CONCLUSIONS BNCT and gamma irradiations showed different genotoxic patterns. To our knowledge, these values represent the first experimental ones obtained for the RA-3 in a biologic model and could be useful for future experimental studies for the application of BNCT to colon carcinoma.
Collapse
|
31
|
Impact of accelerator-based boron neutron capture therapy (AB-BNCT) on the treatment of multiple liver tumors and malignant pleural mesothelioma. Radiother Oncol 2009; 92:89-95. [DOI: 10.1016/j.radonc.2009.01.010] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2008] [Revised: 01/09/2009] [Accepted: 01/11/2009] [Indexed: 11/30/2022]
|
32
|
Kim YJ, Yoon WK, Ryu SY, Chun KJ, Son HY, Cho SW. Histopathological changes of testes and eyes by neutron irradiation with boron compounds in mice. J Vet Sci 2006; 7:19-23. [PMID: 16434844 PMCID: PMC3242080 DOI: 10.4142/jvs.2006.7.1.19] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
This study was performed to investigate the biological effects of boron neutron capture therapy (BNCT) on the testes and eyes in mice using HANARO Nuclear Reactor, Korea Atomic Energy Research Institute. BNCT relies on the high capacity of 10B in capturing thermal neutrons. Sodium borocaptate (BSH, 75 ppm, iv) and boronophenylalanine (BPA, 750 ppm, ip) have been used as the boron delivery agents. Mice were irradiated with neutron (flux: 1.036739E +09, Fluence 9.600200E+12) by lying flat pose for 30 (10 Gy) or 100 min (33 Gy) with or without boron carrier treatment. In 45 days of irradiation, histopathological changes of the testes and eyes were examined. Thirty-three Gy neutron irradiation for 100 min induced testicular atrophy in which some of seminiferous tubules showed complete depletion of spermatogenic germ cells. Lens epithelial cells and lens fiber were swollen and showed granular changes in an exposure time dependent manner. However, boron carrier treatment had no significant effect on the lesions. These results suggest that the examination of histopathological changes of lens and testis can be used as "biological dosimeters" for gauging radiation responses and the HANARO Nuclear Reactor has sufficient capacities for the BNCT.
Collapse
Affiliation(s)
- Yeon-Joo Kim
- College of Veterinary Medicine, Chungnam National University, Daejeon 305-764, Korea
| | | | | | | | | | | |
Collapse
|
33
|
Boron neutron capture therapy. ACTA ACUST UNITED AC 2005. [DOI: 10.1016/s0169-3158(06)80006-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/01/2023]
|
34
|
Suzuki M, Masunaga S, Kinashi Y, Nagata K, Sakurai Y, Nakamatsu K, Nishimura Y, Maruhashi A, Ono K. Intra-arterial administration of sodium borocaptate (BSH)/lipiodol emulsion delivers B-10 to liver tumors highly selectively for boron neutron capture therapy: experimental studies in the rat liver model. Int J Radiat Oncol Biol Phys 2004; 59:260-6. [PMID: 15093923 DOI: 10.1016/j.ijrobp.2003.12.018] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2003] [Revised: 12/08/2003] [Accepted: 12/15/2003] [Indexed: 11/24/2022]
Abstract
PURPOSE Boron neutron capture therapy (BNCT) is particle radiotherapy with alpha ((4)He) particle and recoiled lithium nucleus ((7)Li) derived from a reaction of boron ((10)B) and thermal neutron. We investigated applying BNCT to malignant liver tumors. The purpose of the present study was to reveal the efficacy for administration of emulsion of a boron compound (sodium borocaptate; BSH) and lipiodol via a hepatic artery using a rat liver tumor model. METHODS AND MATERIALS Rat liver tumors were developed by direct injection of Walker 256 cells into the liver parenchyma. BSH (75 mg/kg)/lipiodol (0.3 mL/kg) emulsion was administered via the hepatic artery. Boron concentrations in the tumors, liver, and blood were measured at 1, 6, and 12 h after administration. Neutron capture radiography (NCR) was taken to confirm the selective accumulation of (10)B in the liver tumors. RESULTS Boron concentrations in the liver tumors and the tumor/liver (T/L) boron concentration ratio at 1, 6, and 12 h after administration of BSH/lipiodol emulsion (concentration: T/L ratio) were 479.2 ppm: 4.0, 197.3 ppm: 14.9, and 96.5 ppm: 6.6, respectively. Highly selective irradiation was clearly demonstrated by the NCR images. CONCLUSIONS Intra-arterial administration of BSH/lipiodol emulsion is effective method for delivering high concentration of (10)B selectively to the liver tumors.
Collapse
Affiliation(s)
- Minoru Suzuki
- Radiation Oncology Research Laboratory, Research Reactor Institute, Kyoto University, Kyoto, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Obayashi S, Kato I, Ono K, Masunaga SI, Suzuki M, Nagata K, Sakurai Y, Yura Y. Delivery of 10boron to oral squamous cell carcinoma using boronophenylalanine and borocaptate sodium for boron neutron capture therapy. Oral Oncol 2004; 40:474-82. [PMID: 15006618 DOI: 10.1016/j.oraloncology.2003.09.018] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2003] [Accepted: 09/25/2003] [Indexed: 10/26/2022]
Abstract
Boron neutron capture therapy (BNCT) is a unique radiation therapy in which boron compounds are trapped into tumor cells. To determine the biodistribution of boronophenylalanine (BPA) in nude mice carrying oral squamous cell carcinoma (SCC), BPA was administered at a dose of 250 mg/kg body weight intraperitoneally. Two hours later, (10)B concentration in the tumor was 15.96 ppm and tumor/blood, tumor/tongue, tumor/skin and tumor/bone (10)B concentration ratios were 6.44, 4.19, 4.68 and 4.56, respectively. Two hours after the administration of borocaptate sodium (BSH) at a dose of 75 mg/kg body weight, (10)B concentration in the tumor was 3.61 ppm, and tumor/blood, tumor/tongue, tumor/skin and tumor/bone (10)B concentration ratios were 0.77, 1.05, 0.60 and 0.59, respectively. When cultured oral SCC cells were incubated with BPA or BSH for 2 h and then exposed to thermal neutrons, the proportion of survival cells that were capable of forming cell colonies decreased exponentially, depending on (10)B concentration. BPA-mediated BNCT was more efficient than BSH-mediated BNCT. Addition of boron compounds in the cell suspension during neutron irradiation enhanced the cell-killing effect of the neutrons. These results indicate that BPA is more selectively incorporated into human oral SCC as compared with normal oral tissues, and that both extra- and intra-cellular BPA contribute to the cell-killing effect of BNCT. BPA may be a useful boron carrier for BNCT in the treatment of advanced oral SCC.
Collapse
Affiliation(s)
- Shigeki Obayashi
- Second Department of Oral and Maxillofacial Surgery Osaka University, Graduate School of Dentistry, Osaka 565-0871, Japan
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Suzuki M, Sakurai Y, Masunaga S, Kinashi Y, Nagata K, Ono K. Dosimetric study of boron neutron capture therapy with borocaptate sodium (BSH)/lipiodol emulsion (BSH/lipiodol-BNCT) for treatment of multiple liver tumors. Int J Radiat Oncol Biol Phys 2004; 58:892-6. [PMID: 14967447 DOI: 10.1016/j.ijrobp.2003.09.084] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2003] [Revised: 09/17/2003] [Accepted: 09/22/2003] [Indexed: 12/21/2022]
Abstract
PURPOSE We performed a computational study to investigate the feasibility of borocaptate sodium (BSH)/lipiodol-boron neutron capture therapy (BSH/lipiodol-BNCT) for multiple liver tumors using Simulation Environment for Radiotherapy Applications (SERA), a currently available BNCT treatment planning system. METHODS AND MATERIALS Three treatment plans for BSH/lipiodol-BNCT using two or three epithermal neutron beams in one fraction were generated for 4 patients with multiple liver tumors using the SERA system. The (10)B concentrations in the tumor and the liver assumed in the study were 197.3 and 15.3 ppm, respectively; and were obtained from experimental studies in animals. The therapeutic gain factors for the liver tumors, defined as the minimum dose to the tumor/maximum dose to the liver, and the inhomogeneity index of the thermal neutron fluence for the whole of the liver, defined as the maximum neutron fluence - minimum neutron fluence/mean neutron fluence, were evaluated in each plan. RESULTS Three epithermal neutron beams incident on the anterior, posterior, and right side of the patient can deliver the most homogeneous distribution of thermal neutron fluence to the whole of the liver and provide the greatest therapeutic gain factors for tumors in the right lobe and approximately equal therapeutic gain factors for tumors in the left lobe, compared with the two opposed (anterior-posterior) and two orthogonal (anterior-right) beams. CONCLUSIONS From a dosimetric viewpoint, the BSH/lipiodol-BNCT treatment plan using three epithermal neutron beams is the most suitable for the treatment of multiple liver tumors.
Collapse
Affiliation(s)
- Minoru Suzuki
- Radiation Oncology Research Laboratory, Research Reactor Institute, Kyoto University, Osaka, Japan.
| | | | | | | | | | | |
Collapse
|